Thousand Oaks Biopharmaceuticals, The Integrated CMC Solution Provider Company, delivers solutions that enable your biologics to be accessible and affordable to patients.
Shun Luo Ph.D.
Founder and Chairman
Thousand Oaks Biopharmaceuticals
Thousand Oaks is dedicated to science-based innovation and technology integration.
We have the ultimate goal to enable our partner to deliver more accessibile and affordable biologics to humanity.
How do we measure this?
Manufacturing costs of goods (mCOG), $/kg.
We are excited to lead a group of excellent investors in the direction Thousand Oaks Bio is taking.
TOBIO combines the expertise in cell culture media development, early process development, and full CDMO services to build its high-quality platform for biologics development and manufacturing.
Mr. Liefeng Qu,
Chairman and Partner
New Alliance Capital
Building the world’s largest cell culture manufacturing facility with CDMO capability
Thousand Oaks Biopharmaceuticals Completes $45 Million Series A Financing to Expand Integrated CMC and Build the World Largest Cell Cultural Production Facility in China
January 03, 2019 07:00 AM Eastern Standard Time
THOUSAND OAKS, Calif. & SHANGHAI—(BUSINESS WIRE)—Thousand Oaks Biopharmaceuticals, Inc. (“TOBIO”), a leading integrated global CMC organization including GMP cell culture media and biomanufacturing capabilities today announced the closing of a $45 Million USD Series A financing to advance its phase II CDMO and started its construction of Large Scale Cell Culture Media (LSCCM) cGMP Manufacturing facilities based in Haimen, Nantong (part of greater Shanghai), China.
We are working every day to make sure our organization aligns around your needs. From our culture to our processes to our responsiveness we are committed to make you the center of all we do.
Our Integrated CMC Solutions
Our offer includes:
Our Locations
CHINA
Shanghai, Haimen, & Lanzhou
cGMP Manufacturing and Development Labs
USA